Coming soon

In terms of HIV, CytoDyn is collaborating with amfAR to sponsor the LATCH study, which aims to use leronlimab in combination with bone marrow transplantation for a potential HIV cure. This initiative gained momentum following recent successes in HIV research in Germany. CytoDyn is also working on inflammation-related studies, including trials for chronic inflammation and Alzheimer's disease, with results expected in late 2024 or early 2025.

On the oncology front, CytoDyn has resumed its Triple-Negative Breast Cancer (TNBC) research, collaborating with institutions like MD Anderson and the University of Hawaii. The company is also preparing for a Phase II trial for colorectal cancer, with patient screening set to begin in early 2025 oai_citation:1,September 2024 Letter to Shareholders - CYDY CytoDyn Inc oai_citation:2,CytoDyn Begins Preclinical MASH Study, Results Due Fall 2024 oai_citation:3,September 2024 Letter to Shareholders.

In terms of its MASH (metabolic-associated steatohepatitis) study, results from a preclinical trial are expected this fall, focusing on optimal dosing and potential combination therapies oai_citation:4,CytoDyn Begins Preclinical MASH Study, Results Due Fall 2024.